The Hindu Business Line : Ranbaxy gets nod for Cefprozil

Ranbaxy Laboratories has said it has received approval from the US Food and Drug Administration to manufacture and market Cefprozil for oral suspension USP, 125 mg/5ml and 250 mg/5ml. The Office of Generic Drugs, USFDA has determined the Ranbaxy formulations to be bio-equivalent and have the same therapeutic effect as that of the reference listed drug Cefzil for oral suspension by Bristol Myers Squibb Company Pharmaceutical Research Institute, a company release said. The total annual market sales for Cefprozil are estimated at $93 million.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Reliance, Qualcomm in deadlock over royalty

The growing competitiveness of India Inc

Gillette shifting office base to Mumbai

Asia Pacific plans to set up greenfield brewery in AP

Ranbaxy gets nod for Cefprozil

Chemfab Alkalies plans overseas tie-up

Sakthi Masala gets CSR award

City Tiles sees 20 pc growth on construction boom

Hero Honda June sales up 23%

New office-bearers for HMA